{"id":"W4397007282","doi":"10.1016/j.esmoop.2024.103202","title":"180O IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Centre Hospitalier Universitaire Vaudois","keywords":"Atezolizumab; Medicine; Triple-negative breast cancer; Oncology; Chemotherapy; Breast cancer; Internal medicine; Radiology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00086541,0.0006021477,0.001788364,0.0003199642,0.0002408864,0.0002057528,0.0005886618,0.0001075765,0.003358492],"category_scores_gemma":[0.0001399659,0.0004270997,0.0004266595,0.0009760837,0.0002719167,0.001036685,0.0001476845,0.0004276551,0.00001631854],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005623738,"about_ca_system_score_gemma":0.002012115,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003275558,"about_ca_topic_score_gemma":0.000397356,"domain_scores_codex":[0.9963742,0.0001464481,0.001196063,0.0009176523,0.0005981247,0.0007674344],"domain_scores_gemma":[0.9973265,0.0007644138,0.0004837658,0.0006519535,0.0004425006,0.0003308498],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8136566,0.0007085224,0.000005382064,0.0003451538,0.001630657,0.00008606054,0.001171786,0.0001974032,0.003616445,0.0002046347,0.0006075082,0.1777699],"study_design_scores_gemma":[0.9394705,0.002937281,0.00004062491,0.002272663,0.0007023917,0.0001628587,0.0005249916,0.001789097,0.04123453,0.001089359,0.00925159,0.0005241021],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8632454,0.00504405,0.05163048,0.007865353,0.004748684,0.06193851,0.001791524,0.0005603003,0.003175672],"genre_scores_gemma":[0.9715837,0.0005237093,0.008018713,0.000349854,0.0006111892,0.006092128,0.0001342469,0.0002753231,0.01241115],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1772458,"threshold_uncertainty_score":0.9998181,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05708297713041971,"score_gpt":0.4125401569395417,"score_spread":0.355457179809122,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}